Next Article in Journal
A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90a
Previous Article in Journal
Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccines
Article Menu

Export Article

Open AccessArticle
Cancers 2011, 3(4), 4212-4227; doi:10.3390/cancers3044212

Immunohistochemical Assessment of Expression of Centromere Protein—A (CENPA) in Human Invasive Breast Cancer

1
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada
2
Cancer Research institute, Queen’s University, Kingston, ON K7L 3N6, Canada
3
NCIC Clinical Trials Group, Queen’s University, Kingston, ON K7L 3N6, Canada
4
Department of Oncology, Cancer Center of Southeastern Ontario, Kingston, ON K7L 2V7, Canada
*
Author to whom correspondence should be addressed.
Received: 2 October 2011 / Revised: 24 November 2011 / Accepted: 30 November 2011 / Published: 6 December 2011
View Full-Text   |   Download PDF [934 KB, uploaded 6 December 2011]   |  

Abstract

Abnormal cell division leading to the gain or loss of entire chromosomes and consequent genetic instability is a hallmark of cancer. Centromere protein –A (CENPA) is a centromere-specific histone-H3-like variant gene involved in regulating chromosome segregation during cell division. CENPA is one of the genes included in some of the commercially available RNA based prognostic assays for breast cancer (BCa)—the 70 gene signature MammaPrint® and the five gene Molecular Grade Index (MGISM). Our aim was to assess the immunohistochemical (IHC) expression of CENPA in normal and malignant breast tissue. Clinically annotated triplicate core tissue microarrays of 63 invasive BCa and 20 normal breast samples were stained with a monoclonal antibody against CENPA and scored for percentage of visibly stained nuclei. Survival analyses with Kaplan–Meier (KM) estimate and Cox proportional hazards regression models were applied to assess the associations between CENPA expression and disease free survival (DFS). Average percentage of nuclei visibly stained with CENPA antibody was significantly higher (p = 0.02) in BCa than normal tissue. The 3-year DFS in tumors over-expressing CENPA (>50% stained nuclei) was 79% compared to 85% in low expression tumors ( 60.07; p = 0.06) within our small cohort. To the best of our knowledge, this is the first published report evaluating the implications of increased IHC expression of CENPA in paraffin embedded breast tissue samples. Our finding that increased CENPA expression may be associated with shorter DFS in BCa supports its exploration as a potential prognostic biomarker. View Full-Text
Keywords: CENPA; breast cancer; immunohistochemistry CENPA; breast cancer; immunohistochemistry
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rajput, A.B.; Hu, N.; Varma, S.; Chen, C.-H.; Ding, K.; Park, P.C.; Chapman, J.-A.; SenGupta, S.K.; Madarnas, Y.; Elliott, B.E.; Feilotter, H.E. Immunohistochemical Assessment of Expression of Centromere Protein—A (CENPA) in Human Invasive Breast Cancer. Cancers 2011, 3, 4212-4227.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top